[{"id":"0e743df4-4d78-48c0-81d7-be2811a46a8b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04431024","created_at":"2021-01-18T21:20:26.688Z","updated_at":"2025-02-25T15:11:35.608Z","phase":"","brief_title":"Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome","source_id_and_acronym":"NCT04431024","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BAP1","pipe":" | ","alterations":" BAP1 mutation","tags":["BAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BAP1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 800","initiation":"Initiation: 03/30/2021","start_date":" 03/30/2021","primary_txt":" Primary completion: 06/30/2038","primary_completion_date":" 06/30/2038","study_txt":" Completion: 06/30/2038","study_completion_date":" 06/30/2038","last_update_posted":"2025-02-13"},{"id":"14a6bde6-48dd-43fd-b20a-941240b312eb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04515836","created_at":"2021-01-18T21:38:23.683Z","updated_at":"2025-02-25T14:59:18.583Z","phase":"Phase 2","brief_title":"Olaparib in Patients With HRD Malignant Mesothelioma","source_id_and_acronym":"NCT04515836","lead_sponsor":"University of Chicago","biomarkers":" BAP1","pipe":" | ","alterations":" BAP1 mutation","tags":["BAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BAP1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • cisplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 02/19/2021","start_date":" 02/19/2021","primary_txt":" Primary completion: 04/15/2025","primary_completion_date":" 04/15/2025","study_txt":" Completion: 04/15/2025","study_completion_date":" 04/15/2025","last_update_posted":"2024-10-23"},{"id":"47252750-bcc0-4057-a521-b65b2a9c492c","acronym":"IDENTHY-K","url":"https://clinicaltrials.gov/study/NCT05014698","created_at":"2021-08-20T14:53:01.605Z","updated_at":"2024-07-02T16:34:36.831Z","phase":"","brief_title":"IDEntification of New Predisposition Genes in Differentiated THYroid Cancer","source_id_and_acronym":"NCT05014698 - IDENTHY-K","lead_sponsor":"Nantes University Hospital","biomarkers":" BAP1 • DICER1","pipe":" | ","alterations":" BAP1 mutation","tags":["BAP1 • DICER1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BAP1 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 02/23/2022","start_date":" 02/23/2022","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-06-10"},{"id":"566dbbb6-eabe-4dfb-be9c-7161bcda7964","acronym":"","url":"https://clinicaltrials.gov/study/NCT05960773","created_at":"2023-07-27T18:08:58.951Z","updated_at":"2024-07-02T16:34:37.145Z","phase":"Phase 2","brief_title":"Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma","source_id_and_acronym":"NCT05960773","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BAP1","pipe":" | ","alterations":" BAP1 mutation","tags":["BAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BAP1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inqovi (decitabine/cedazuridine)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 01/31/2024","start_date":" 01/31/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-06-07"},{"id":"78b229da-43da-49fb-9bb1-8557ce0bcba9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03830229","created_at":"2021-01-18T18:54:52.823Z","updated_at":"2024-07-02T16:34:38.028Z","phase":"","brief_title":"Long Term Follow-up of Mesothelioma Patients and Their Family Members With Germline Mutations in BAP1 and Other Genes","source_id_and_acronym":"NCT03830229","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • BAP1","pipe":" | ","alterations":" TP53 mutation • BAP1 mutation","tags":["TP53 • BAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • BAP1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 03/13/2019","start_date":" 03/13/2019","primary_txt":" Primary completion: 07/06/2026","primary_completion_date":" 07/06/2026","study_txt":" Completion: 07/05/2027","study_completion_date":" 07/05/2027","last_update_posted":"2024-06-05"},{"id":"a42b730f-7cb0-4a7e-b9c9-5253a2b3eeb8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04390737","created_at":"2022-05-12T19:53:40.351Z","updated_at":"2024-07-02T16:35:04.605Z","phase":"Phase 1/2","brief_title":"Evaluate the Safety and Clinical Activity of HH2853","source_id_and_acronym":"NCT04390737","lead_sponsor":"Haihe Biopharma Co., Ltd.","biomarkers":" ARID1A • BAP1","pipe":" | ","alterations":" ARID1A mutation • BAP1 mutation • EZH2 mutation • SMARCA4 mutation","tags":["ARID1A • BAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ARID1A mutation • BAP1 mutation • EZH2 mutation • SMARCA4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HH2853"],"overall_status":"Recruiting","enrollment":" Enrollment 254","initiation":"Initiation: 09/08/2020","start_date":" 09/08/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-09"},{"id":"bd0915a0-fd20-4277-b54e-97bf1a6410c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03452774","created_at":"2021-01-18T17:01:36.578Z","updated_at":"2024-07-02T16:35:14.464Z","phase":"","brief_title":"SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","source_id_and_acronym":"NCT03452774","lead_sponsor":"Massive Bio, Inc.","biomarkers":" EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703","pipe":" | ","alterations":" HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation","tags":["EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 50000","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-03-15"},{"id":"a3b94b21-6e56-4be0-94d8-6e762635e9e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04792463","created_at":"2021-03-11T13:52:41.075Z","updated_at":"2024-07-02T16:35:31.698Z","phase":"","brief_title":"Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome","source_id_and_acronym":"NCT04792463","lead_sponsor":"Mohamed Abdel-Rahman","biomarkers":" BAP1","pipe":" | ","alterations":" BAP1 mutation","tags":["BAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BAP1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 03/03/2015","start_date":" 03/03/2015","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2023-10-25"},{"id":"c66f765b-84b8-4be7-b6e5-f176047b0b9e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04633902","created_at":"2021-01-19T20:37:04.111Z","updated_at":"2024-07-02T16:35:59.576Z","phase":"Phase 2","brief_title":"Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation","source_id_and_acronym":"NCT04633902","lead_sponsor":"California Pacific Medical Center Research Institute","biomarkers":" BRAF • BRCA1 • BRCA2 • ARID1A • BAP1 • BRCA • CHEK2 • RAD51 • FANCA • BRIP1 • RAD50 • ARID2 • BARD1 • FANCD2 • RAD54B","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • BRAF mutation • BRAF V600 • ATM mutation • ARID1A mutation • BAP1 mutation • CHEK2 mutation • BRIP1 mutation • FANCA mutation • RAD50 mutation • BARD1 mutation","tags":["BRAF • BRCA1 • BRCA2 • ARID1A • BAP1 • BRCA • CHEK2 • RAD51 • FANCA • BRIP1 • RAD50 • ARID2 • BARD1 • FANCD2 • RAD54B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • BRAF mutation • BRAF V600 • ATM mutation • ARID1A mutation • BAP1 mutation • CHEK2 mutation • BRIP1 mutation • FANCA mutation • RAD50 mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 03/03/2021","start_date":" 03/03/2021","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2022-12-06"},{"id":"88667f1b-98a0-4422-b87f-eee21f1cbfb9","acronym":"CHANGEABLE","url":"https://clinicaltrials.gov/study/NCT04508803","created_at":"2021-01-18T21:36:41.487Z","updated_at":"2024-07-02T16:36:08.019Z","phase":"Phase 2","brief_title":"Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer","source_id_and_acronym":"NCT04508803 - CHANGEABLE","lead_sponsor":"Fudan University","biomarkers":" HER-2 • BRCA1 • BRCA2 • PTEN • BAP1 • CDK12 • CHEK2 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • FANCF • WRN • FANCM • FANCD2 • FANCE • FANCC","pipe":" | ","alterations":" HER-2 positive • BRCA2 mutation • BRCA1 mutation • HR positive • HER-2 negative • ATM mutation • PALB2 mutation • CDK12 mutation • BAP1 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • HR positive + HER-2 negative • RAD50 mutation • BARD1 mutation • BLM mutation • CHEK1 mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation • CHEK1 expression","tags":["HER-2 • BRCA1 • BRCA2 • PTEN • BAP1 • CDK12 • CHEK2 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • FANCF • WRN • FANCM • FANCD2 • FANCE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • BRCA2 mutation • BRCA1 mutation • HR positive • HER-2 negative • ATM mutation • PALB2 mutation • CDK12 mutation • BAP1 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • HR positive + HER-2 negative • RAD50 mutation • BARD1 mutation • BLM mutation • CHEK1 mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation • CHEK1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • cisplatin • Zejula (niraparib) • Puyouheng (pucotenlimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 09/14/2020","start_date":" 09/14/2020","primary_txt":" Primary completion: 11/20/2022","primary_completion_date":" 11/20/2022","study_txt":" Completion: 12/28/2022","study_completion_date":" 12/28/2022","last_update_posted":"2022-06-30"},{"id":"71f7d7d5-8dbb-4ee0-9fc8-5c916cce0f90","acronym":"","url":"https://clinicaltrials.gov/study/NCT02860286","created_at":"2021-01-17T17:30:41.405Z","updated_at":"2024-07-02T16:36:32.130Z","phase":"Phase 2","brief_title":"Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma","source_id_and_acronym":"NCT02860286","lead_sponsor":"Epizyme, Inc.","biomarkers":" BAP1","pipe":" | ","alterations":" BAP1 mutation","tags":["BAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BAP1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tazverik (tazemetostat)"],"overall_status":"Completed","enrollment":" Enrollment 74","initiation":"Initiation: 07/01/2016","start_date":" 07/01/2016","primary_txt":" Primary completion: 06/01/2018","primary_completion_date":" 06/01/2018","study_txt":" Completion: 05/01/2019","study_completion_date":" 05/01/2019","last_update_posted":"2021-04-09"},{"id":"911e26b2-7e38-409e-ba7a-812ebe71146c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03531840","created_at":"2021-01-18T17:23:53.468Z","updated_at":"2024-07-02T16:36:32.134Z","phase":"Phase 2","brief_title":"Olaparib in People With Malignant Mesothelioma","source_id_and_acronym":"NCT03531840","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BAP1 • BRCA","pipe":" | ","alterations":" BAP1 mutation","tags":["BAP1 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BAP1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 07/11/2018","start_date":" 07/11/2018","primary_txt":" Primary completion: 12/04/2019","primary_completion_date":" 12/04/2019","study_txt":" Completion: 10/21/2020","study_completion_date":" 10/21/2020","last_update_posted":"2021-04-09"},{"id":"b36e2ef1-bfb8-462b-a6c3-083d5b53e72d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01925599","created_at":"2021-01-18T08:41:43.994Z","updated_at":"2024-07-02T16:36:32.797Z","phase":"","brief_title":"BAP1 Testing in Instance Choroidal Nevi or Uveal Melanoma","source_id_and_acronym":"NCT01925599","lead_sponsor":"Amy C Schefler, MD","biomarkers":" BAP1","pipe":" | ","alterations":" BAP1 mutation","tags":["BAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BAP1 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 133","initiation":"Initiation: 07/01/2013","start_date":" 07/01/2013","primary_txt":" Primary completion: 01/01/2022","primary_completion_date":" 01/01/2022","study_txt":" Completion: 01/01/2022","study_completion_date":" 01/01/2022","last_update_posted":"2021-03-26"},{"id":"6620b65a-3bbd-43be-bc87-a299b4dfa310","acronym":"","url":"https://clinicaltrials.gov/study/NCT04764084","created_at":"2021-02-21T12:52:13.701Z","updated_at":"2024-07-02T16:36:34.306Z","phase":"Phase 1","brief_title":"Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors","source_id_and_acronym":"NCT04764084","lead_sponsor":"Beijing Cancer Hospital","biomarkers":" HER-2 • BRCA1 • BRCA2 • HRD • BAP1 • CHEK2 • RAD51 • FANCA • BRIP1","pipe":" | ","alterations":" BRCA1 mutation • HER-2 negative • ATM mutation • PALB2 mutation • BAP1 mutation • CHEK2 mutation • BRIP1 mutation • FANCA mutation • RAD51 mutation","tags":["HER-2 • BRCA1 • BRCA2 • HRD • BAP1 • CHEK2 • RAD51 • FANCA • BRIP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • HER-2 negative • ATM mutation • PALB2 mutation • BAP1 mutation • CHEK2 mutation • BRIP1 mutation • FANCA mutation • RAD51 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Zejula (niraparib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 04/01/2021","start_date":" 04/01/2021","primary_txt":" Primary completion: 11/01/2021","primary_completion_date":" 11/01/2021","study_txt":" Completion: 02/28/2023","study_completion_date":" 02/28/2023","last_update_posted":"2021-02-22"},{"id":"b90a3987-3bf3-4d39-98e9-7ee2f01b8aca","acronym":"","url":"https://clinicaltrials.gov/study/NCT01773655","created_at":"2021-01-18T07:49:06.912Z","updated_at":"2024-07-02T16:36:43.671Z","phase":"","brief_title":"Clinical and Histopathologic Characteristics of BAP1 Mutations","source_id_and_acronym":"NCT01773655","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BAP1","pipe":" | ","alterations":" BAP1 mutation","tags":["BAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BAP1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 196","initiation":"Initiation: 01/01/2013","start_date":" 01/01/2013","primary_txt":" Primary completion: 06/30/2020","primary_completion_date":" 06/30/2020","study_txt":" Completion: 06/30/2020","study_completion_date":" 06/30/2020","last_update_posted":"2020-07-01"},{"id":"2ff87f9f-b793-4fba-92c8-1665d12300ce","acronym":"","url":"https://clinicaltrials.gov/study/NCT02834234","created_at":"2021-01-18T13:54:30.988Z","updated_at":"2024-07-02T16:37:30.233Z","phase":"","brief_title":"Genomic Analysis of Peritoneal Mesothelioma by CGH Arrays","source_id_and_acronym":"NCT02834234","lead_sponsor":"Hospices Civils de Lyon","biomarkers":" BAP1","pipe":" | ","alterations":" BAP1 mutation","tags":["BAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BAP1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 05/01/2013","start_date":" 05/01/2013","primary_txt":" Primary completion: 01/01/2016","primary_completion_date":" 01/01/2016","study_txt":" Completion: 01/01/2016","study_completion_date":" 01/01/2016","last_update_posted":"2016-07-26"}]